Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2005 2
2006 4
2007 3
2008 4
2009 3
2010 2
2011 5
2012 8
2013 5
2014 13
2015 14
2016 17
2017 10
2018 15
2019 24
2020 18
2021 26
2022 19
2023 26
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Results by year

Filters applied: . Clear all
Page 1
Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary group.
Zatelli MC, Faggiano A, Argentiero A, Danesi R, D'Oronzo S, Fogli S, Franchina T, Giorgino F, Marrano N, Giuffrida D, Gori S, Marino G, Mazzilli R, Monami M, Montagnani M, Morviducci L, Natalicchio A, Ragni A, Renzelli V, Russo A, Sciacca L, Tuveri E, Aimaretti G, Avogaro A, Candido R, Di Maio M, Silvestris N, Gallo M. Zatelli MC, et al. Among authors: gori s. Cancer Treat Rev. 2024 Apr 3;126:102734. doi: 10.1016/j.ctrv.2024.102734. Online ahead of print. Cancer Treat Rev. 2024. PMID: 38604051 Review.
Dual-Energy CT in Oncologic Imaging.
Foti G, Ascenti G, Agostini A, Longo C, Lombardo F, Inno A, Modena A, Gori S. Foti G, et al. Among authors: gori s. Tomography. 2024 Feb 23;10(3):299-319. doi: 10.3390/tomography10030024. Tomography. 2024. PMID: 38535766 Free PMC article. Review.
Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
Musacchio L, Palluzzi E, Di Napoli M, Lauria R, Ferrandina G, Angioli R, Bergamini A, Corrado G, Perniola G, Cassani C, Savarese A, Gori S, Greco F, De Angelis C, Zafarana E, Giannarelli D, Cinieri S, Mosconi AM, Raspagliesi F, Pignata S, Scambia G, Lorusso D. Musacchio L, et al. Among authors: gori s. Gynecol Oncol. 2024 Jan 25;184:24-30. doi: 10.1016/j.ygyno.2024.01.022. Online ahead of print. Gynecol Oncol. 2024. PMID: 38277918
Correction: Repotrectinib's Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer.
Metro G, Gariazzo E, Costabile S, Baglivo S, Roila F, Colamartini F, Palumbo B, Chiarini P, Gori S, Conti A, Marcomigni L, Bellezza G, Lunardi G. Metro G, et al. Among authors: gori s. Oncol Ther. 2024 Mar;12(1):173-174. doi: 10.1007/s40487-023-00258-z. Oncol Ther. 2024. PMID: 38170387 Free PMC article. No abstract available.
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program.
Passiglia F, Lucia Reale M, Lo Russo G, Pasello G, Minuti G, Bulotta A, Galetta D, Pelizzari G, Sini C, Bria E, Roca E, Pilotto S, Genova C, Metro G, Citarella F, Chiari R, Cortinovis D, Delmonte A, Russo A, Tiseo M, Cerea G, Carta A, Scotti V, Vavalà T, Brambilla M, Buffoni L, Buosi R, Catania C, Gori S, Grisanti S, Agustoni F, Garbo E, Malapelle U, Novello S. Passiglia F, et al. Among authors: gori s. Lung Cancer. 2024 Jan;187:107444. doi: 10.1016/j.lungcan.2023.107444. Epub 2023 Dec 15. Lung Cancer. 2024. PMID: 38157806 Free article.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016).
Pellegrino B, Tommasi C, Serra O, Gori S, Cretella E, Ambroggi M, Frassoldati A, Bisagni G, Casarini C, Bria E, Carbognin L, Fiorio E, Mura A, Zamagni C, Gianni L, Zambelli A, Montemurro F, Tognetto M, Todeschini R, Missale G, Campanini N, Silini EM, Maglietta G, Musolino A. Pellegrino B, et al. Among authors: gori s. J Immunother Cancer. 2023 Nov 28;11(11):e007667. doi: 10.1136/jitc-2023-007667. J Immunother Cancer. 2023. PMID: 38016718 Free PMC article. Clinical Trial.
199 results